STAT

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

The biggest names in biotech descend on San Francisco for #JPM19. Is it worth it for some of the smallest names in the industry?

For four days in January, the biggest names in biotech descend on the J.P. Morgan Healthcare Conference in San Francisco to unveil splashy merger and acquisition announcements, offer out-of-the-box meditations on drug pricing, and schmooze.

But some of the smallest and newest names in biotech are there, too, trying not to get lost in the noise.

These companies aren’t making headline-grabbing presentations or hosting big parties. But the conference gives tiny startups and even small- and mid-size public companies a pivotal — and unmissable — opportunity, executives at three different companies told STAT. For them, the conference is their chance to

You're reading a preview, sign up to read more.

More from STAT

STAT6 min readWellness
Opinion: Ebola Vaccine For Pregnant Women: One Step Closer But Still More To Go
Protecting fetuses from harmful exposures is a laudable goal. But pregnancy shouldn't automatically exclude women from receiving lifesaving therapies like the #Ebola vaccine.
STAT2 min readPolitics
Amgen, Merck, And Eli Lilly Sue Over Trump Administration Policy To Require Drug Prices In TV Ads
Amgen, Merck, Eli Lilly, and the Association of National Advertisers sued the Trump administration over a new policy to require drug prices in TV ads.
STAT4 min readSociety
Opinion: Cost-cutting Jeopardizes Many Americans’ Access To Lifesaving Oxygen Therapy
We wouldn't tolerate a pharmacy failing to provide prescribed medication. We shouldn't tolerate companies failing to deliver prescribed oxygen therapy, though it happens all the time.